Market Overview - The Hang Seng Index reached a four-year high last week, but experienced a technical pullback due to a hawkish Federal Reserve chair nomination, indicating a risk-off sentiment in global equity markets [1] - The market sentiment index moved from panic to optimism within 16 days, suggesting a shift in investor sentiment [1] - Current market volatility is expected to persist, but it is more likely to be a correction rather than a reversal of market performance [1] Earnings and Revenue Expectations - Non-financial earnings expectations have been revised upward by 0.4% over the past four weeks, while revenue expectations have been slightly downgraded by 0.1% [2] - The sectors with the most significant upward revisions in earnings expectations include non-ferrous metals (7.7%), military industry (4.0%), and electric new energy (1.8%) [2] Capital Flow - Foreign capital continues to flow into Hong Kong stocks, with net inflows reaching $2.8 billion, up from $1.95 billion the previous week [3] - Active foreign capital has seen a continuous inflow for three weeks, with a record weekly inflow of $640 million [3] - The nomination of Kevin Warsh as the next Federal Reserve chair has led to short-term volatility, but the medium-term liquidity outlook remains accommodative [3] Market Sentiment - The market sentiment index has risen to 62.1, indicating an optimistic outlook [4] - Factors contributing to this optimism include strong net inflows from southbound capital and high buying intensity [4] Investment Recommendations - Companies with earnings certainty should be considered as core holdings, while opportunities to increase allocations in technology and cyclical materials should be explored during market corrections [5] - Focus on sectors showing upward trends, such as AI-related industries, semiconductor manufacturing, and innovative pharmaceuticals [5]

Fixed Income - The report analyzes the new regulatory framework for insurance companies, highlighting five major changes aimed at improving asset-liability management [9][10] - The insurance industry's solvency indicators declined in Q3 2025, attributed to increased equity capital usage and dual pressure on liabilities [11] - Investment returns improved due to rising long-term bond yields and favorable A-share performance, reducing overall industry risk [12] - A selection of insurance subordinated bonds with specific criteria is recommended for investment, including those from major state-owned insurance companies [14] Pharmaceutical Industry - The pharmaceutical index fell by 3.31% recently, with a notable trend of Chinese innovative drugs expanding into international markets [15][17] - Companies like China Biopharmaceutical are enhancing their R&D capabilities through acquisitions and self-developed products, positioning themselves for potential overseas opportunities [18] - A focus on innovative drugs is recommended, with specific companies highlighted for their strong fundamentals and potential for stock price recovery [19] New Consumption - Ruoyu Chen and Wancheng Group are projected to see significant profit growth in 2025, driven by their proprietary brand business and operational efficiency improvements [21][23] - The government is promoting new service consumption growth points, aiming to enhance service supply and consumer experience [25][26] - The snack retail sector is evolving, with companies like Mingming Hen Mang rapidly expanding and innovating to meet consumer demands [24] North Exchange - The North Exchange indices saw over 6% growth in January 2026, indicating a market rebound and highlighting specific sectors for investment opportunities [28][29] - The overall market liquidity remains ample, with a focus on structural investment opportunities in specialized and innovative enterprises [29][30] Media - Alibaba's FY2026Q3 revenue is expected to reach 288.1 billion yuan, with cloud business growth anticipated despite a slowdown in e-commerce [32]

Core Viewpoints - The recent market pullback is seen as a technical correction rather than a reversal, primarily driven by the rapid rise in stock prices and the hawkish stance of the newly nominated Federal Reserve Chair [2] - The current market sentiment has shifted to an optimistic zone, with the emotional index reaching 62.1, indicating a potential for continued volatility in the short term [5][49] - The three driving factors for market space in the first quarter remain intact: improved liquidity, resonance in the funding environment, and upward revisions in profit expectations [2] Fundamental Analysis - Non-financial profit expectations have been revised upward by 0.4% over the past four weeks, while revenue expectations have been slightly adjusted downward by 0.1% [3] - The sectors with the most significant upward revisions in profit expectations include non-ferrous metals (7.7%), military industry (4.0%), and new energy (1.8%) [3] - The official manufacturing PMI for January stands at 49.3, reflecting demand-side pressures, although there are positive signals in price recovery [3] Funding Environment - Foreign capital continues to flow into the Hong Kong stock market, with net inflows reaching $2.8 billion, up from $1.95 billion the previous week [4] - Active foreign capital has seen a continuous inflow for three weeks, with a record weekly inflow of $640 million, while passive foreign capital remains at a high level [4] - The nomination of Kevin Warsh as the next Federal Reserve Chair has led to short-term volatility, but the medium-term liquidity outlook remains relatively loose [4] Market Sentiment - The market sentiment has quickly transitioned into an optimistic zone, with the emotional index indicating a potential accumulation of short-term volatility risks [5][49] - The sentiment indicators, including net inflows from southbound funds and the AH premium score, remain high, suggesting strong market participation [5] Investment Recommendations - Emphasis on companies with earnings certainty as a core holding, with a focus on the technology and cyclical materials sectors for potential incremental investments [6] - Short-term attention should be given to leading companies' earnings reports and industry developments, particularly in the AI supply chain [6] - Mid-term strategies should continue to overweight resource stocks, insurance, and local Hong Kong stocks after stabilization [6]

Investment Rating - The report recommends an "Overweight" rating for solid-state batteries, innovative drugs, and new consumption sectors, while suggesting a "Neutral+" rating for humanoid robots and AI applications [5][10][21]. Core Insights - The report highlights a focus on solid-state batteries, innovative drugs, and new consumption as key investment themes, indicating a positive outlook for these sectors [5][10]. - The report notes that the overall emerging industry is showing a strong fundamental outlook with a neutral technical perspective, suggesting potential for growth despite recent fluctuations [16]. Summary by Relevant Sections Investment Themes - **Solid-State Batteries**: Rated "Overweight" with a strong technical outlook, indicating a recovery from a low position. The industry is moving towards commercialization with significant developments from companies like Geely [5][10]. - **Innovative Drugs**: Also rated "Overweight", with a stable outlook as the National Medical Products Administration has approved multiple innovative drugs, enhancing market confidence [5][10]. - **New Consumption**: Rated "Overweight", with initiatives in Beijing to promote new consumption landmarks, indicating a supportive environment for growth [5][10]. - **Humanoid Robots**: Rated "Neutral+", with a moderate technical outlook. The sector is experiencing a transition from prototypes to mass production, which could enhance market opportunities [5][10]. - **AI Applications**: Rated "Neutral+", with signs of recovery. The commercialization of AI applications is seen as a turning point, with significant investments from major companies [5][10]. Market Trends - The report indicates that the overall emerging industry has returned to below the mean plus two standard deviations, with moderate rotation intensity and average crowding levels, suggesting a potential for rebound in profitability expectations [16][18]. - Recent events, such as the launch of new products and approvals in the innovative drug sector, are expected to drive growth and investor interest [10][11].

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical industry [4] Core Viewpoints - The Chinese biopharmaceutical sector is expected to enter a new era of innovative drug exports in 2026, with significant opportunities arising from strategic acquisitions and internal research and development [3][8] - The report emphasizes the importance of selecting strong fundamental innovative drug stocks that have undergone sufficient adjustments, as well as actively monitoring new medical technologies and companies poised for recovery in 2026 [4][41] Summary by Sections Industry Performance - From January 26 to January 30, the pharmaceutical index fell by 3.31%, underperforming the CSI 300 index by 3.39%. Notably, the market has seen a significant adjustment in the innovative drug sector since August 2025, with the lowest holdings in active funds since 2021 [5][21] - The report highlights that 58 stocks rose while 407 stocks fell during the week, with notable gainers including Cap Bio (+26.49%) and Hualan Biological (+12.80%) [5][22] Company Insights - China Biopharmaceutical is enhancing its core competitiveness through strategic acquisitions and self-research, which is expected to lead to more opportunities for international expansion. The acquisition of Hegia in January 2026 and Lixin Pharmaceutical in July 2025 are key moves to strengthen its pipeline in chronic diseases and oncology [8][13] - The report identifies Hegia's siRNA delivery technology as a significant advancement, allowing for long-lasting treatment options in chronic diseases, while Lixin's unique LM-TME platform is expected to enhance the company's capabilities in oncology [9][11][14] Investment Recommendations - The report suggests focusing on innovative drug companies such as Heng Rui Medicine, Xin Li Tai, and China Biopharmaceutical, as well as companies involved in new medical technologies like AI healthcare and brain-computer interfaces [41][43] - It also highlights the potential for recovery in the medical device and pharmaceutical manufacturing sectors in 2026, recommending stocks that are currently undervalued [41][42] Market Trends - The report notes that the Chinese pharmaceutical industry has completed a transition from generic to innovative drugs, with companies like Heng Rui Medicine and China Biopharmaceutical leading the way in innovation [41][42] - The aging population and increasing healthcare demands are expected to drive growth in the sector, supported by a stable increase in medical insurance revenues and the development of a multi-tiered payment system [41][42]

Investment Rating - The report does not explicitly state an investment rating for the surgical robot industry, but it indicates a positive outlook for growth and development in the sector. Core Insights - The surgical robot industry in China is entering a rapid development phase, supported by national policies and capital investment, with significant advancements in technology and market demand [13]. - The report highlights the transition from a capital-driven to a value-driven model in the surgical robot sector, emphasizing the importance of clinical applications and technological integration [13]. - The approval process for surgical robots by the NMPA has accelerated, particularly for orthopedic surgical robots, which dominate the market in terms of the number of products approved [30][28]. Summary by Sections Market Overview - The surgical robot market in China is characterized by a growth in sales volume, with a total of 332 units sold in the first 11 months of 2025, reflecting a year-on-year increase of 3.75% [34]. - The sales revenue for surgical robots reached 2.973 billion yuan, showing a slight decline of 0.87% year-on-year, indicating a structural transition rather than a market downturn [34]. Technological Advancements - Innovations in remote operation, miniaturization, and AI assistance are driving the development of surgical robots, with products like the TUMAI® remote surgical robot achieving significant milestones in cross-border surgeries [16][19]. - The introduction of AI-assisted surgical robots is enhancing precision in surgeries, with products capable of 3D reconstruction and personalized surgical planning [16]. Regulatory Developments - The National Healthcare Security Administration has established a pricing framework for surgical robots, which is expected to facilitate market growth by clarifying reimbursement policies and pricing structures [27][26]. - The pricing guidelines categorize surgical robot services into navigation, participation in execution, and precision execution, linking them to main surgical procedures [27]. Market Segmentation - The orthopedic surgical robot segment holds the largest market share, accounting for 50% of the total NMPA-approved surgical robots from 2014 to 2024, followed by neurosurgical robots [30]. - The report indicates a significant potential for growth in emerging fields such as vascular surgery robots, with increasing demand and technological advancements [34]. Competitive Landscape - The report identifies key players in the surgical robot market, including domestic manufacturers that are rapidly gaining market share as regulatory barriers for imports increase [45]. - The competitive landscape is shifting as domestic products receive NMPA approval, challenging the previously dominant imported products [45].

Investment Rating - The report does not explicitly state an investment rating for the surgical robot industry, but it highlights a positive outlook for growth and innovation in the sector. Core Insights - The surgical robot industry in China is entering a rapid development phase, supported by national policies and capital investment, with significant advancements in technology and market demand [13]. - The report emphasizes the transition from a capital-driven to a value-driven model in the surgical robot sector, indicating a shift towards more sustainable growth and clinical applications [13]. - The approval process for surgical robots by the NMPA has accelerated, particularly for domestic products, with orthopedic surgical robots leading in the number of approvals [30]. Summary by Sections Market Overview - The surgical robot market in China is characterized by a growth in sales volume, with a total of 332 units sold in the first 11 months of 2025, reflecting a year-on-year increase of 3.75% [34]. - The sales revenue for surgical robots reached 2.973 billion yuan, showing a slight decline of 0.87% year-on-year, indicating a structural transition rather than a market downturn [34]. Technological Advancements - Innovations in remote operation, miniaturization, and AI assistance are driving the development of surgical robots, with notable products like the first remote surgical robot approved in China [16][19]. - The report highlights the introduction of AI-assisted surgical robots that enhance precision and efficiency in surgeries, marking a significant technological leap in the industry [16]. Regulatory Developments - The National Healthcare Security Administration has established a pricing framework for surgical robots, which is expected to facilitate market growth by clarifying reimbursement policies and pricing structures [27][26]. - The report notes that the establishment of a clear payment system is crucial for the adoption of surgical robots in hospitals, as high costs and long return periods can deter procurement [27]. Market Segmentation - The orthopedic surgical robot segment dominates the market, accounting for 50% of the NMPA approvals from 2014 to 2024, with a strong growth trajectory expected in this area [30]. - The report identifies the laparoscopic surgical robot and orthopedic surgical robot as the two largest segments in the market, with significant potential for expansion in emerging fields [41]. Future Outlook - The report projects substantial growth in the surgical robot market, with expectations for increased penetration rates and market size driven by technological advancements and policy support [44]. - The anticipated CAGR for the laparoscopic surgical robot market from 2024 to 2033 is estimated at 30.4%, indicating robust future demand [44].

Core Viewpoint - The Chinese surgical robot industry is entering a rapid development phase, driven by policy support, capital investment, and technological advancements, with significant progress in various fields such as orthopedics and neurosurgery [13][21]. Market Overview - The CITIC Medical Index fell by 3.33% this week, underperforming the CSI 300 Index by 3.41 percentage points, ranking 22nd among 30 primary industries [8]. - The top ten stocks by growth this week included Cap Bio, Hualan Biological, and Dezheng Health, while the biggest losers were *ST Sailong and Vcare Pharmaceuticals [8]. Industry and Company Events - The surgical robot market is characterized by a shift from capital-driven to value-driven development, with increasing applications in remote surgery and AI-assisted decision-making [13][21]. - The NMPA has accelerated the approval of surgical robots, with orthopedic surgical robots accounting for 50% of the approved products from 2014 to 2024, maintaining the highest share [22]. Investment Themes - The innovative drug sector is transitioning from quantity to quality, emphasizing differentiated products and internationalization by 2025 [11]. - The medical device sector is witnessing a recovery in bidding volumes for imaging equipment, with ongoing updates in home medical devices supported by subsidies [11]. - The CXO and life sciences services are expected to see a rebound in investment, with a focus on high-profit elasticity companies as the industry matures [11]. Technological Progress - Remote operation, miniaturization, and AI assistance are key trends in the surgical robot sector, with products like the TUMAI® remote surgical robot achieving significant milestones in cross-border surgeries [17][19]. - The first AI-assisted orthopedic surgical robot, ROPA HIP, has been approved, showcasing advancements in surgical simulation technology [17]. Regulatory Developments - The National Medical Insurance Administration (NMPA) has established a pricing system for surgical robots, which is expected to enhance the industry's growth by clarifying reimbursement standards [21]. - The introduction of a legal and clear pricing project for surgical robots is anticipated to provide institutional support for innovation and development in the industry [21]. Sales and Market Dynamics - The sales volume of surgical robots in China reached 332 units in the first 11 months of 2025, reflecting a 3.75% year-on-year increase, while sales revenue decreased by 0.87% [27]. - The orthopedic surgical robot segment showed a significant growth of 17.81% in volume and 21.62% in revenue, indicating a robust demand in specialized fields [27]. Market Segmentation - The market for surgical robots is dominated by laparoscopic and orthopedic surgical robots, which accounted for 42% and 32% of the market share, respectively, in 2024 [25]. - Emerging fields such as vascular surgery robots are expected to present substantial market potential as the industry evolves [27].

2026年开年，资金借道跨境ETF持续向港股科技板块聚集。 Wind数据显示，2026年1月以来，超160只港股ETF（仅统计跨境ETF，下同）合计获得283.89亿元净流入。其中，约九成资金流入了港股通互 联网ETF、恒生科技ETF等科技主题产品。 同时，净申购增量及基金净值增长共同推动港股ETF的规模扩容提速：截至2026年1月29日，其总规模逼近8000亿元，较2025年底增加了近790 亿元。 从产品端看，近期，港股科技主题基金产品有望加速"上新"。 据21世纪经济报道记者粗略统计，自2026年开年以来，公募基金管理人至少已上报了28只港股主题基金（尚待批复），投资方向覆盖了港股科 技、医药、红利、消费等多个赛道。而科技主题基金依旧占据C位。 科技ETF持续"吸金" 经历一段时间的疲软之后，港股各行业板块在2026年初有所反弹。资金流入港股ETF的趋势也仍在延续。 据Wind统计，截至2026年1月29日，开年以来，160多只港股ETF共计获得283.89亿元净流入。 其中，共有10只产品的"吸金"规模达到10亿元以上，分别是：广发港股通非银ETF、富国港股通互联网ETF、恒生科技ETF天弘、华泰柏瑞 ...

Core Viewpoint - The article highlights a significant inflow of funds into Hong Kong's technology sector through cross-border ETFs, indicating a growing interest in technology-themed investments as the market rebounds in early 2026 [1][3]. Fund Inflows and Performance - Since the beginning of 2026, over 160 Hong Kong ETFs have seen a net inflow of 28.389 billion yuan, with approximately 90% of this capital directed towards technology-themed products such as the Hong Kong Internet ETF and the Hang Seng Technology ETF [1][3][4]. - The total scale of Hong Kong ETFs has approached 800 billion yuan, marking an increase of nearly 79 billion yuan since the end of 2025, representing an 11% growth [6]. Product Development - At least 28 new Hong Kong-themed funds have been reported by public fund managers since the start of 2026, focusing primarily on technology, healthcare, and consumer sectors, with technology funds being the most prominent [1][8][9]. - The top 10 funds attracting significant capital include several technology ETFs, with inflows exceeding 10 billion yuan for products like the GF Hong Kong Non-Bank ETF and the FT Hong Kong Internet ETF [4][5]. Fund Performance - Most Hong Kong ETFs have recorded positive returns since the beginning of 2026, with several funds in the healthcare and non-bank sectors achieving returns over 10% [5][6]. - The performance of technology-themed ETFs has been particularly strong, with the Hong Kong Internet ETF and the Hang Seng Technology ETF yielding returns of approximately 8.9% and 8%, respectively [5]. Long-term Investment Outlook - The article emphasizes the long-term growth potential of the technology sector in Hong Kong, driven by global capital and talent influx, as well as favorable trends in artificial intelligence and innovation [10][11]. - The article also notes the potential for investment in upstream resources and companies expanding internationally, indicating a broader strategy for capital allocation in the Hong Kong market [10].